U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H25N3O5S
Molecular Weight 383.4642
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MEROPENEM ANHYDROUS

SMILES

C[C@]1([H])[C@]2([H])[C@@]([H])([C@@]([H])(C)O)C(=O)N2C(=C1S[C@@]3([H])C[C@@]([H])(C(=O)N(C)C)NC3)C(=O)O

InChI

InChIKey=DMJNNHOOLUXYBV-PQTSNVLCSA-N
InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1

HIDE SMILES / InChI

Molecular Formula C17H25N3O5S
Molecular Weight 383.4642
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |

Meropenem (generic name: meropenem hydrate) is a carbapenem antibiotic for injection showing a strong antibacterial activity to a wide range of bacteria strains from Gram-positive bacteria, Gram-negative bacteria to anaerobic bacteria. It is used as single agent therapy for the treatment of the following infections: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci. This drug also used in case of Intra-abdominal Infections for the treatment complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. In addition is used the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitides. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Meropenem product with such superior effectiveness and safety has been approved for marketing by 100 countries or more in the world (as of March 2004) since its first launch in Italy in 1994.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
MERREM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

Launch Date

8.3531517E11
Primary
MERREM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

Launch Date

8.3531517E11
Curative
MERREM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.

Launch Date

8.3531517E11
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
2001
Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
2001
[Antibiotic therapy of cystic fibrosis in children].
2001
[Antimicrobial activities and mechanisms of carbapenem resistance in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp].
2001 Aug
Antimicrobial susceptibility of potentially pathogenic halophilic vibrios isolated from seafood.
2001 Aug
Meropenem and continuous renal replacement.
2001 Aug
In vitro activity of fosfomycin in combination with various antistaphylococcal substances.
2001 Aug
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
2001 Dec
Empirical monotherapy with meropenem in serious bacterial infections in children.
2001 Dec
Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000.
2001 Dec
Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies.
2001 Dec
Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.
2001 Dec
Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000).
2001 Dec
MYSTIC program: summary of European data from 1997 to 2000.
2001 Dec
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA).
2001 Dec
Determining the value of antimicrobial surveillance programs.
2001 Dec
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001.
2001 Dec
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus.
2001 Dec 14
[Microbiological monitoring of the microbic strain stability to antibacterial preparations in surgical in-patient clinics].
2001 Feb
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae].
2001 Jul
Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem.
2001 Jul 20
Use of broad spectrum antibiotics in six non-university Swiss hospitals.
2001 Jul 28
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.
2001 Jul 30
Ertapenem: a new carbapenem.
2001 Jun
Treatment of nosocomial pneumonia: an experience with meropenem.
2001 Jun
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). I. Susceptibility distribution].
2001 May
[A case of eosinophilic pneumonia possibly due to ifenprodil].
2001 Nov
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
2001 Nov
Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy.
2001 Oct
Failure of cefotaxime and meropenem to eradicate meningitis caused by an intermediately susceptible Streptococcus pneumoniae strain.
2001 Oct
[A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
2001 Sep
[Susceptibility to penicillin and 13 antimicrobial agents in erythromycin-resistant viridans group streptococci isolated from blood cultures].
2001 Sep
[Antimicrobial activities of carbapenems and fourth generation cephems against clinically isolated strains].
2001 Sep
Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.
2001 Sep
Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.
2001 Sep
Isolation and culture of airway epithelial cells from chronically infected human lungs.
2001 Sep
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.
2001 Sep
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety.
2001 Sep 3
Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium.
2001 Sep-Oct
Antibiotic persistence: the role of spontaneous DNA repair response.
2001 Winter
Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases.
2002 Feb
Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
2002 Feb
Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units.
2002 Feb
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.
2002 Feb
Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several beta-lactamase-producing Gram-negative strains.
2002 Feb
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient.
2002 Jan
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital.
2002 Jan
Primary liver abscess caused by one clone of Klebsiella pneumoniae with two colonial morphotypes and resistotypes.
2002 Jan
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).
2002 Mar
Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities.
2002 Mar 15
Patents

Sample Use Guides

Adult Patients: The recommended dose of MERREM I.V. is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P.aeruginosa, a dose of 1 gram every 8 hours is recommended. Pediatric Patients 3 Months of Age and Older: For pediatric patients 3 months of age and older, the MERREM I.V. dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). Pediatric patients weighing over 50 kg should be administered MERREM I.V. at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 gram every 8 hours for intra-abdominal infections and 2 grams every 8 hours for meningitis. MERREM I.V. should be given as intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes. There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose.
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment:: Meropenem was 4-64 times more active than imipenem against gram-negatives, including Enterobacteriaceae organisms, Pseudomonas aeruginosa, Burkholderia cepacia, Neisseria meningiditis, and Haemophilus influenzae. Imipenem was up to 2-4 times more active than meropenem against some gram-positive cocci, including Enterococcus faecalis. Meropenem, unlike imipenem or ceftazidime, was bactericidal for all strains of Enterobacteriaceae, P. aeruginosa, and gram-positive cocci tested at < or = 8 times the MIC.
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 14:10:06 UTC 2021
Edited
by admin
on Sat Jun 26 14:10:06 UTC 2021
Record UNII
YOP6PX0BAO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MEROPENEM ANHYDROUS
Common Name English
MEROPENEM [MI]
Common Name English
MEROPENEM, ANHYDROUS
Common Name English
MEROPENEM [INN]
Common Name English
(4R,5S,6S)-3-(((3S,5S)-5-(DIMETHYLCARBAMOYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
MEROPENEM [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C260
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
NDF-RT N0000175496
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
WHO-ATC J01DH02
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
Code System Code Type Description
CAS
96036-03-2
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
FDA UNII
YOP6PX0BAO
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
RXCUI
1546029
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
PRIMARY RxNorm
EVMPD
SUB08778MIG
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
PUBCHEM
441130
Created by admin on Sat Jun 26 14:10:07 UTC 2021 , Edited by admin on Sat Jun 26 14:10:07 UTC 2021
PRIMARY
HSDB
8019
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
INN
6396
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
NCI_THESAURUS
C61833
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
EVMPD
SUB49628
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
EPA CompTox
96036-03-2
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY
MERCK INDEX
M7240
Created by admin on Sat Jun 26 14:10:06 UTC 2021 , Edited by admin on Sat Jun 26 14:10:06 UTC 2021
PRIMARY Merck Index
Related Record Type Details
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
EXCRETED UNCHANGED
Related Record Type Details
METABOLITE -> PARENT
Mediator: DHP-I
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC Adult
PHARMACOKINETIC
Children
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Population
Children and Adults
Population
Infants < mo